Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen[1] specialized in the production of anti-biotics, including Vancomycin[2] and Bacitracin.[3]
The company's US base of operations is in Buffalo Grove, Illinois,[4][5] with additional facilities in Ohio, and North Carolina.[6]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are:[8]
Previously the company also produced:
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.[4][10][11][12][13]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.[14]
